Elucid Launches AI Software for Arterial Plaque Measurement
Elucid has launched PlaqueIQ, an AI-based image analysis software that quantifies plaque build-up to evaluate a patient’s risk of cardiovascular disease (CVD).
PlaqueIQ is the first and only FDA-cleared plaque analysis software indicated for the carotid vasculature, cleared by the US Food and Drug Administration (FDA) in October 2024.
The gold standard of business intelligence.
Elucid’s offering combines business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Author’s summary: Elucid launches PlaqueIQ for CVD risk evaluation.